The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edema

Trial Profile

The study for the effect of intravitreous injection of ranibizumab (product name: Lucentis) and subthreshold laser photocoagulation on diabetic macular edema

Completed
Phase of Trial: Phase III

Latest Information Update: 06 Apr 2017

At a glance

  • Drugs Ranibizumab (Primary)
  • Indications Diabetic macular oedema
  • Focus Therapeutic Use
  • Most Recent Events

    • 03 Apr 2017 Status changed from active, no longer recruiting to completed.
    • 17 Feb 2017 Status changed from recruiting to active, no longer recruiting.
    • 21 Apr 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top